1. Home
  2. NAMS vs CASH Comparison

NAMS vs CASH Comparison

Compare NAMS & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • CASH
  • Stock Information
  • Founded
  • NAMS 2019
  • CASH 1954
  • Country
  • NAMS Netherlands
  • CASH United States
  • Employees
  • NAMS N/A
  • CASH N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • NAMS Health Care
  • CASH Finance
  • Exchange
  • NAMS Nasdaq
  • CASH Nasdaq
  • Market Cap
  • NAMS 2.2B
  • CASH 1.9B
  • IPO Year
  • NAMS N/A
  • CASH N/A
  • Fundamental
  • Price
  • NAMS $18.11
  • CASH $78.05
  • Analyst Decision
  • NAMS Strong Buy
  • CASH Buy
  • Analyst Count
  • NAMS 6
  • CASH 2
  • Target Price
  • NAMS $42.83
  • CASH $92.00
  • AVG Volume (30 Days)
  • NAMS 694.5K
  • CASH 158.7K
  • Earning Date
  • NAMS 05-08-2025
  • CASH 07-23-2025
  • Dividend Yield
  • NAMS N/A
  • CASH 0.26%
  • EPS Growth
  • NAMS N/A
  • CASH 10.71
  • EPS
  • NAMS N/A
  • CASH 7.36
  • Revenue
  • NAMS $47,140,000.00
  • CASH $731,383,000.00
  • Revenue This Year
  • NAMS N/A
  • CASH $13.95
  • Revenue Next Year
  • NAMS N/A
  • CASH $5.74
  • P/E Ratio
  • NAMS N/A
  • CASH $10.61
  • Revenue Growth
  • NAMS 586.97
  • CASH 6.51
  • 52 Week Low
  • NAMS $14.06
  • CASH $51.98
  • 52 Week High
  • NAMS $27.29
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 47.80
  • CASH 47.77
  • Support Level
  • NAMS $16.79
  • CASH $76.98
  • Resistance Level
  • NAMS $19.58
  • CASH $78.77
  • Average True Range (ATR)
  • NAMS 0.94
  • CASH 1.69
  • MACD
  • NAMS -0.12
  • CASH -0.66
  • Stochastic Oscillator
  • NAMS 47.07
  • CASH 18.38

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: